-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, C3wEisaMUSk0hohDZOOfA6QLCwbAOWq+8N8eVO+jx2Kz9gnb2H66RW7Vxx/8PD2l AZbPlFupao5tS4gIdqEabA== 0001181431-10-047355.txt : 20100920 0001181431-10-047355.hdr.sgml : 20100920 20100920164542 ACCESSION NUMBER: 0001181431-10-047355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100916 FILED AS OF DATE: 20100920 DATE AS OF CHANGE: 20100920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gionco David CENTRAL INDEX KEY: 0001456864 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 101080829 MAIL ADDRESS: STREET 1: 9 HOWELL DRIVE CITY: FAR HILLS STATE: NJ ZIP: 07931 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 4 1 rrd286696.xml GIONCO BLA PERFORMANCE VESTING X0303 4 2010-09-16 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001456864 Gionco David SAVIENT PHARMACEUTICALS, INC. ONE TOWER CENTER, 14TH FLOOR EAST BRUNSWICK NJ 08816 0 1 0 0 Group Vice President, CFO Common Stock, $0.01 par value per share 2010-09-16 4 A 0 22918 20.27 A 54073 D Common Stock, $0.01 par value per share 2010-09-16 4 F 0 8118 20.27 D 45955 D The right to receive these shares is pursuant to a performance based restricted stock grant, a portion of which vested on September 16, 2010. These shares were automatically surrendered to the Company pursuant to Rule 16b-3 of the Securities Exchange Act to cover tax withholding obligations in connection with the vesting of performance based restricted stock granted on November 22, 2009. /s/ Irina Ishak as Attorney-In-Fact for David Gionco 2010-09-20 -----END PRIVACY-ENHANCED MESSAGE-----